Evidence review of hair loss and facial changes linked to GLP‑1 weight‑loss drugs

Weight‑loss injections that target the glucagon‑like peptide‑1 (GLP‑1) pathway, such as Wegovy and Mounjaro, have surged in use worldwide, prompting a parallel rise in reports of adverse reactions. Digestive disturbances have been consistently documented among users, while other complaints—including nausea, vomiting and, more recently, potential hair loss—have generated increasing public and scientific interest. Researchers this week highlighted a possible association between GLP‑1 agonists and alopecia, adding to a growing list of side‑effects that patients and clinicians are monitoring.

The new analysis underscores that the evidence base for many reported outcomes varies in quality. While gastrointestinal effects are supported by multiple controlled trials, the link to hair loss rests on limited observational data and case reports, prompting calls for larger, systematic studies to confirm causality. Experts caution that not all anecdotal claims have undergone rigorous scrutiny, and they advise healthcare providers to weigh the benefits of GLP‑1 therapy against the spectrum of verified and unverified risks. Ongoing research will be essential to delineate which side‑effects are substantiated and to guide informed treatment decisions.